About AnaCardio
AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Solna, Sweden
Team Size
11-50
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
anacardio.com
Domain Registered Date
Apr 19, 2017
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $70,968,750 · Series-B+
anacardio.com
- Capital Raise
Raised $19,000,000 · Venture Round
fundraisingfox.com
- Capital Raise
Series-A announced
fundraisingfox.com
- Milestone
Website domain registered
anacardio.com
Investors & Backers
3B Ventures
Flerie Invest
Fredrik Ljungström
Helsinn Healthcare
Industrifonden
Innovestor
LLD Nybohov Invest AB
Novo Holdings
Pureos Bioventures
Sound Bioventures
The Ljungstrom Family Office
Funding History
Series-B+
· Sep 30, 2026
$70,968,750 anacardio.com
Venture Round
· Jan 9, 2025
$19,000,000 fundraisingfox.com
Series-A
· Sep 7, 2022
Undisclosed fundraisingfox.com
Founders & Leadership
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026